Stefanie Koristka

Company: Intellia Therapeutics

Job title: Principal Scientist

Seminars:

Generating Potent, Stable & Off-the-Shelf Synthetic Tregs from CD4+ Tconv for the Treatment of Colitis & Beyond 1:30 pm

Outlining the process of converting CD4 cells to synthetic Tregs (synTregs) via gene engineering Highlighting the benefits of synTregs compared to tTregs as cellular therapy Showcasing preclinical efficacy data from GvHD and colitis mouse modelsRead more

day: Day 2 Treg Cell Therapy Track PM